CA3212301A1 - Cell compositions derived from dedifferentiated reprogrammed cells - Google Patents

Cell compositions derived from dedifferentiated reprogrammed cells

Info

Publication number
CA3212301A1
CA3212301A1 CA3212301A CA3212301A CA3212301A1 CA 3212301 A1 CA3212301 A1 CA 3212301A1 CA 3212301 A CA3212301 A CA 3212301A CA 3212301 A CA3212301 A CA 3212301A CA 3212301 A1 CA3212301 A1 CA 3212301A1
Authority
CA
Canada
Prior art keywords
cells
cell
heregulin
cell population
neuregulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212301A
Other languages
English (en)
French (fr)
Inventor
Alan D. Agulnick
Olivia Kelly
Yuki OHI
Allan Robins
Thomas Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viacyte Inc
Original Assignee
Viacyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/761,078 external-priority patent/US9109245B2/en
Application filed by Viacyte Inc filed Critical Viacyte Inc
Publication of CA3212301A1 publication Critical patent/CA3212301A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3212301A 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells Pending CA3212301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/761,078 2013-02-06
US13/761,078 US9109245B2 (en) 2009-04-22 2013-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
CA2898431A CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2898431A Division CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Publications (1)

Publication Number Publication Date
CA3212301A1 true CA3212301A1 (en) 2014-08-14

Family

ID=50239931

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3212301A Pending CA3212301A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
CA2898431A Active CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2898431A Active CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Country Status (8)

Country Link
EP (1) EP2954045A1 (https=)
JP (5) JP6517702B2 (https=)
AU (5) AU2014214879A1 (https=)
CA (2) CA3212301A1 (https=)
HK (1) HK1218139A1 (https=)
IL (5) IL311689B2 (https=)
RU (2) RU2675928C2 (https=)
WO (1) WO2014124172A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
AU2015300020B2 (en) 2014-08-04 2021-04-08 Orizuru Therapeutics, Inc. Method for proliferation of pancreatic progenitor cells
DK3443073T3 (da) * 2016-04-14 2024-09-02 Janssen Biotech Inc Differentiering af pluripotente stamceller til intestinale mellemtarmendodermceller
CN111334463B (zh) * 2016-05-18 2024-02-20 学校法人庆应义塾 类器官培养用细胞培养基、培养方法及类器官
EP3587560A4 (en) 2017-01-27 2020-12-16 Kaneka Corporation Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells
CN111565707A (zh) 2017-06-14 2020-08-21 森玛治疗公司 用于递送治疗物的装置和方法
EP3654996A4 (en) * 2017-07-21 2021-03-24 Semma Therapeutics, Inc. REAGGREGATION OF PANCREAS BETA CELLS FROM STEM CELLS
US20210292708A1 (en) * 2018-08-03 2021-09-23 Kyoto University Cell production method
BR112021004815A2 (pt) * 2018-09-19 2021-06-01 Takeda Pharmaceutical Company Limited células produtoras de insulina, medicamento, e, métodos para produzir células produtoras de insulina, para gerar células do tipo ilhota pancreática, para tratar diabetes mellitus, para melhorar e/ou manter o controle dos níveis de glicose em jejum e pós-prandial em um paciente e para reduzir o risco de hipoglicemia em um paciente com diabetes mellitus
WO2020243665A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
WO2020243666A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
AU2020282355B2 (en) 2019-05-31 2023-11-02 Viacyte, Inc. A biocompatible membrane composite
CN114401752B (zh) 2019-05-31 2023-04-04 W.L.戈尔及同仁股份有限公司 具有受控氧扩散距离的细胞封装装置
IL300105A (en) 2020-07-31 2023-03-01 Vertex Pharma Pancreatic endocrine cell differentiation
CN119948151A (zh) * 2022-09-26 2025-05-06 国立大学法人京都大学 胰腺内胚层细胞的制造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE397959T1 (de) * 1999-04-06 2008-07-15 Genentech Inc Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
CA2435826A1 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America Differentiation of stem cells to pancreatic endocrine cells
CN101310012B (zh) * 2005-10-14 2012-05-09 明尼苏达大学董事会 非胚胎干细胞分化成具有胰腺表型的细胞
AU2007254766A1 (en) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
AU2009313870B2 (en) 2008-11-14 2013-07-11 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9109245B2 (en) * 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US8685726B2 (en) * 2009-04-27 2014-04-01 Viacyte, Inc. Small molecules supporting pluripotent cell growth and methods thereof
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Also Published As

Publication number Publication date
RU2018144412A (ru) 2019-03-25
JP6721752B2 (ja) 2020-07-15
JP2016506736A (ja) 2016-03-07
JP7250731B2 (ja) 2023-04-03
IL283088A (en) 2021-06-30
IL290717B1 (en) 2024-06-01
IL290717A (en) 2022-04-01
EP2954045A1 (en) 2015-12-16
IL311689A (en) 2024-05-01
AU2022200075A1 (en) 2022-02-03
JP2020178694A (ja) 2020-11-05
AU2023202507B2 (en) 2025-12-04
RU2675928C2 (ru) 2018-12-25
AU2023202507A1 (en) 2023-05-11
AU2022200075B2 (en) 2023-02-02
IL239953A0 (en) 2015-08-31
IL311689B2 (en) 2025-12-01
AU2019201314A1 (en) 2019-03-14
WO2014124172A1 (en) 2014-08-14
AU2019201314B2 (en) 2021-10-14
IL311689B1 (en) 2025-08-01
JP6517702B2 (ja) 2019-05-22
AU2022200075C1 (en) 2023-07-06
RU2018144412A3 (https=) 2020-02-14
IL321825A (en) 2025-08-01
AU2026201562A1 (en) 2026-03-19
RU2754089C2 (ru) 2021-08-26
JP2025000625A (ja) 2025-01-07
JP2019146578A (ja) 2019-09-05
RU2015131279A (ru) 2017-03-13
CA2898431C (en) 2023-10-17
AU2014214879A1 (en) 2015-07-30
IL290717B2 (en) 2024-10-01
IL283088B (en) 2022-04-01
CA2898431A1 (en) 2014-08-14
HK1218139A1 (zh) 2017-02-03
JP2023017838A (ja) 2023-02-07
JP7550830B2 (ja) 2024-09-13
IL239953B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
US20240409900A1 (en) Cell encapsulation device comprising a pancreatic progenitor cell population
AU2023202507B2 (en) Cell compositions derived from dedifferentiated reprogrammed cells
AU2023201602B2 (en) In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
EP2421957B1 (en) Cell compositions derived from dedifferentiated reprogrammed cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230908

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250415

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250415

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250610

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250924